Tissue/blood collection

MIPPaC: Understanding the mechanisms underlying weight loss in people with cancer by investigating changes to metabolism and the immune system

Learn More


Precision-Panc: Advancing personalised medicine treatment strategies for pancreatic cancer

Learn More


Pancrea_tive: Investigating tumour-stroma heterogeneity in human pancreatic cancer and pancreatic diseases

Learn More


PORTICO-Trans: A feasibility study looking at the immune system in tumours, comparing samples collected during surgery to those taken afterwards

Learn More


Locally advanced

GRECO-2: A Randomised, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

Learn More


STARPAC2 (Primus-05): Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer

Learn More


Operable PDAC

Portico-SABR: Investigate the effects and safety of SABR treatment given to patients with operable pancreatic cancer prior to surgery to remove the tumour

Learn More


Metastatic - 1st or 2nd line

daNIS-2: A randomised, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Learn More


PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

Learn More


PemOla: A phase II study combining pembrolizumab (anti-PD-1R Ab) with olaparib (PARP inhibitor) in metastatic PDAC patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/Mb

Learn More


Metastatic - 2nd line and beyond

ATRiUM: A Phase I clinical trial looking at AZD6738 (ATR inhibitor) in combination with Gemcitabine

Learn More


Porcupine 2: A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care who have the RNF43 rearrangement.

Learn More